Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
about
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat CancerA first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsNovel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.Targeting the oncogenic Met receptor by antibodies and gene therapy.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Nanobody-based cancer therapy of solid tumors.MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.
P2860
Q26739702-C9406C5A-FEBC-4D73-ACEB-E4836EA9A279Q33424270-29BEA83F-414A-4D83-A396-9A0995856BF5Q33888876-D7B62350-042F-4B8C-8656-594733A39948Q35214544-92822B57-D2BB-496A-B4C6-B52A1996E421Q38216590-ACF5CDC4-866E-47B8-879F-94EBBDFF9B4BQ38239580-D8143162-A4F8-4F8F-B131-BD9B6915AFA2Q38322471-CD49F593-E5CA-4299-BCF8-6EE1CEE8606FQ38476204-BE87BE45-DF8A-4159-970C-676B0122E361Q38781568-BF1C28B7-377D-4FDD-9BD1-1790A5B5CEB0Q41490164-7F04178D-F88B-41C9-A2D8-18D6F5673AA5Q47099672-23C4A933-23BE-46E0-BB7A-8A2388DAB9A2Q47134203-DDB21CB1-1477-4472-A031-4E57E891E4EAQ49261196-EFD92907-D330-4155-B4FE-1B7252DD770FQ52362264-75A2FFCB-DC6A-4D1F-A51E-CC4B6D1464D2Q52590705-981CC8DE-9A14-45AA-AD69-A77BD1D86129Q52657511-8C825E43-D2CA-4301-9490-0F6BCC48A2C7Q53789447-1B9D36E3-4994-4821-96D2-AD7CB9676CD5
P2860
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@en
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@nl
type
label
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@en
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@nl
prefLabel
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@en
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
@nl
P2093
P2860
P50
P356
P1476
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment
@en
P2093
Cedric Ververken
Magne Børset
Siv Helen Moen
Tinneke Denayer
P2860
P304
P356
10.1111/EJH.12185
P577
2013-09-16T00:00:00Z